Replies to post #421510 on NorthWest Biotherapeutics Inc (NWBO)

[sukus]

The 80% could be from this article.

“Most cancer drugs only achieve clinical benefits in a limited percentage of the patients with the type of cancer being targeted (e.g., 25 – 30% of the patients). In contrast, DCVax has achieved clinical benefits (i.e., longer delay in disease progression and longer extension of survival than with standard of care treatment) in over 80% of the patients who have received DCVax in clinical trials to date. “

https://www.houstonmethodist.org/738_servicesandspecialties/2044_servicesandspecialities_neurologyandneurosurgery/2181_servicesandspecialities_locations/2183_servicesandspecialities_neurologicalinstitutetexasmedicalcenterhouston/2185_servicesandspecialities_clinicalprograms/609_forhealthcareprofessionals_kennethrpeakbrainandpituitarytreatmentcenter/newpage_peakcenter_clinicaltrial_intro/newpage_peakcenter_clinical-trials_dc-vax/